Friday, 01 May 2020 09:29 PM MYT
Cobra Biologics is one of the firms working to make a potential vaccine known as ChAdOx1 nCoV-19 being developed by scientists at the University of Oxford. “ more than enough for clinical trials, but also potentially a start to stock up for commercial supply,” Coleman told Reuters, adding that it could have capacity for up to two million doses in repeat batches.
Coleman said AstraZeneca’s involvement could help with the rapid scaling-up of the vaccine on a global stage, but said that Cobra Biologics and two other contract development and manufacturing organisations with a similar capacity that were already involved would still play a pivotal role. Coleman said that processes that might previously have taken years were being boiled down to five months, and that safety work already carried out on a Middle East respiratory syndrome vaccine could help speed up the development of a Covid-19 vaccine.